You are here


In Mozambique, MHRP works with local researchers to gain a better understanding of the country’s HIV epidemic and expand the country’s capacity to perform future HIV vaccine trials. 

MHRP’s expansion of research activities into Mozambique provides scientists the opportunity to test future vaccine candidates against the predominant HIV subtype (C) circulating in this part of the world. 

This research is a part of a collaborative effort to create a sustainable HIV vaccine research infrastructure in Mozambique in partnership with the National Ministry of Health/National Institute of Health/Polana Çanico Health Research and Training Center in Maputo. 

Research Studies


In 2014, the site was selected as a part of MHRP’s Clinical Trial Unit to receive funding from the National Institute of Allergy and Infectious Diseases (NIAID) to join the HIV Vaccine Trials Network (HVTN) and conduct research. In 2016, the site began HVTN 703 (AMP Study), a Phase I study testing broad and potent monoclonal antibody (bNAb) VRC01 for HIV prevention. This site will also take part in HVTN vaccine research trials that build upon the success of the RV144 HIV vaccine trial, which was led by MHRP in Thailand.

TaMoVac I and II HIV Vaccine Studies

MHRP assists the National Institute of Health and the Plana Çanico Health Research and Training Center in Maputo, which tests an MVA vaccine developed by MHRP and the Laboratory of Viral Diseases/NIAID. The Program provides the MVA, which is delivered after initial vaccination with a DNA vaccine and is developed by the Karolinska Institute in Sweden. In addition, MHRP provides Good Clinical Practice (GCP) monitoring of this clinical trial.

HIV Incidence Studies

The RV363 cohort study will determine HIV incidence and prevalence in Mozambique. Over the course of the study, the cohort participates in quarterly follow-up visits to assess the retention rate. 

The trial also serves as a mechanism to advance the clinical, laboratory, data management, quality assurance, and community engagement capacity for future complex HIV vaccine trials.